Tempest Therapeutics (TPST) Net Cash Flow (2012 - 2025)

Tempest Therapeutics has disclosed Net Cash Flow across 14 years of filings, most recently posting $193000.0 for Q4 2025.

• In Q4 2025, Net Cash Flow fell 97.53% year-over-year to $193000.0; the TTM figure through Dec 2025 stood at -$22.6 million (down 151.74% YoY), while the FY2025 annual figure was -$22.6 million, down 151.74% from the prior year.
• Net Cash Flow came in at $193000.0 for Q4 2025 at Tempest Therapeutics, up from -$6.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $41.0 million in Q2 2021 to a low of -$11.6 million in Q4 2022.
• Average Net Cash Flow over 5 years is -$533500.0, with a median of -$6.6 million recorded in 2023.
• Year-over-year, Net Cash Flow soared 343.64% in 2023 and sank 501.58% in 2025.
• Over 5 years, Net Cash Flow stood at -$8.0 million in 2021, then slumped by 44.13% to -$11.6 million in 2022, then soared by 343.64% to $28.2 million in 2023, then plunged by 72.31% to $7.8 million in 2024, then tumbled by 97.53% to $193000.0 in 2025.
• Per Business Quant data, the three most recent Net Cash Flow figures were $193000.0 in Q4 2025, -$6.8 million in Q3 2025, and -$7.2 million in Q2 2025.